Promising results for drug candidate CS1
This press release reports that over the 12 months of their Expanded Access Program enrolling ten patients, the majority of patients with pulmonary arterial hypertension who completed treatment with drug candidate CS1 maintained or improved their functional and biomarker status, and that CS1 showed a favourable safety and tolerability profile. A Phase IIb trial for CS1 begins this summer.
Smartlead leans toward outreach, so its fit for drafting, replying, and polishing deserves a closer look, and this Smartlead analysis covers its strengths and limits in those areas.
The BTC is aimed at people who are curious about Bitcoin and blockchain but prefer explanations written in plain language.